Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB(1) and VR(1) receptors.
about
Why do cannabinoid receptors have more than one endogenous ligand?Vascular targets for cannabinoids: animal and human studiesThe role of endocannabinoids system in fatty liver disease and therapeutic potentialsPathophysiology of portal hypertensionThe neuroprotective impact of the leak potassium channel TASK1 on stroke development in mice.TASK1 modulates inflammation and neurodegeneration in autoimmune inflammation of the central nervous system.Mechanisms of TNFalpha-induced cardiac dysfunction in cholestatic bile duct-ligated mice: interaction between TNFalpha and endocannabinoids.Beneficial metabolic effects of CB1R anti-sense oligonucleotide treatment in diet-induced obese AKR/J mice.Recent advances in the understanding of the role of the endocannabinoid system in liver diseases.Endocannabinoids in liver disease.Update on the role of cannabinoid receptors after ischemic stroke.Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioningEndocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats.Endocannabinoids and liver disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseasesEndocannabinoids and the control of energy homeostasis.The endocannabinoid system and liver diseases.Mechanisms involved in oleamide-induced vasorelaxation in rat mesenteric resistance arteries.Targeting the endocannabinoid system: to enhance or reduce?Endocannabinoids and liver disease. V. endocannabinoids as mediators of vascular and cardiac abnormalities in cirrhosis.Endocannabinoids and cardiac contractile function: pathophysiological implications.Signal transduction via cannabinoid receptors.Physiopathology of splanchnic vasodilation in portal hypertension.Endothelial dysfunction in the regulation of cirrhosis and portal hypertension.Cardiovascular abnormalities in obstructive cholestasis: the possible mechanisms.The endocannabinoid system in advanced liver cirrhosis: pathophysiological implication and future perspectives.Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis.Cardiohepatic syndrome.Mesenteric artery responsiveness to acetylcholine and phenylephrine in cirrhotic rats challenged with endotoxin: the role of TLR4.Inhibitors of monoacylglycerol lipase, fatty-acid amide hydrolase and endocannabinoid transport differentially suppress capsaicin-induced behavioral sensitization through peripheral endocannabinoid mechanisms.Effect of (-)-Delta(9)-tetrahydrocannabinoid on the hepatic redox state of mice.Augmentation of endogenous cannabinoid tone modulates lipopolysaccharide-induced alterations in circulating cytokine levels in rats.Cardiac abnormalities in cirrhotic children: pre- and post-liver transplantation.Effect of biliary cirrhosis on neurogenic relaxation of rat gastric fundus and anococcygeus muscle: role of nitric oxide pathway
P2860
Q26862444-6FE52344-517D-4137-BC96-D3DA57040EB4Q26862515-4B6F6173-17F6-4DE7-BCDC-6CBBDCB7B331Q27009466-E0EB1ABD-62AF-455A-8102-B72E4597A5FBQ27026406-10713F30-D8AB-46FF-B7A9-547FC286F6DFQ30418200-874B5738-F1ED-4EC1-8CA4-4B6A0D3EA846Q30433284-0FE2DFE2-8D5F-4F2E-8BA5-DF19D96B9ACDQ34216434-6C538CBD-B1CE-405A-9B79-BF605E73B251Q34369293-41E60333-6F28-4AEF-B610-90A8CDAEA12AQ34550846-C2D9CE0F-1346-4895-982B-42DF92BE4248Q34776919-686B2E65-CF02-4BA1-9AF6-06D7F5F82AC9Q35915645-0916EF86-95A4-4DC3-963A-ABE7FCFA02FAQ36416372-7F11BD34-6C86-41AF-8F70-9247BC3BC290Q36426811-1D565B2D-A019-4954-A716-48F1A218ED2AQ36647969-2A101925-1DE9-4DC0-A0BA-747598AC27D0Q36981004-FFE5B65F-5976-4343-9688-D4E57F06BE22Q37143574-429BF661-C390-4303-8A2E-2D4A81655988Q37148175-F55FC210-00B3-4F15-8FBB-A0CA92717128Q37150745-6BF2355C-0818-4239-B48D-3A115FC72394Q37243665-13E26E3B-00C1-4CD4-B751-A59BFC9F7F02Q37401757-BE85E9C4-357D-44C4-9555-384C8B26792EQ37617453-0D98B677-F344-4CB9-82B6-1432E005D5E7Q37821307-1DA38C31-0DF9-45A2-8330-CCC11C8119B3Q37899947-486E6FFD-6D56-4E4A-A454-A9A875EED09DQ38004171-4A0EC6E6-6421-448C-9E5A-95293F1F8E02Q38124458-1CAE4D69-FD6D-4237-B53D-00A4B19F253FQ38195834-0DB012FB-24D7-43F4-A83A-841EC633F24CQ38267664-2EEFEE89-8EA6-4CBA-A13B-DD7BE87A543CQ41227808-430CD159-1F9E-4E52-BB67-6ECE10826B6AQ42034148-CF8BEC80-73E1-4748-A1B6-27F3A9F006D8Q43072572-9148D499-C1C0-4891-BD55-7908EAA7B52AQ46660450-968A44A1-F303-4B70-BCC0-9FA8E2577D15Q50972269-994F50AF-4F37-4E9D-9853-40D136727B57Q57148924-97798745-63FA-4792-A555-DA8B010C4779
P2860
Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB(1) and VR(1) receptors.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Anandamide mediates hyperdynam ...... via CB(1) and VR(1) receptors.
@en
type
label
Anandamide mediates hyperdynam ...... via CB(1) and VR(1) receptors.
@en
prefLabel
Anandamide mediates hyperdynam ...... via CB(1) and VR(1) receptors.
@en
P2093
P2860
P356
P1476
Anandamide mediates hyperdynam ...... via CB(1) and VR(1) receptors
@en
P2093
P2860
P304
P356
10.1038/SJ.BJP.0706928
P407
P577
2006-10-16T00:00:00Z